HER2 plays important roles in the tumorigenesis of breast cancer, ovarian cancer and gastric cancer [9] and Trastuzumab, a monoclonal antibody against HER2, has been approved for the treatment of GC [10]. Here, ERBB2 is linked to ovarian carcinoma.